Prévention de la progression radiographique chez les patients à haut risque atteints de polyarthrite rhumatoïde traités par filgotinib dans les études de phase III : Revue narrative des analyses post hoc
Rheumatol Ther. 2023;10(6):1399–1415 doi: 10.1007/s40744-023-00590-w
Findings from post hoc analyses extend the knowledge base for radiographic benefits of filgotinib in patients with RA.
In practice, poor prognostic factors (PPFs) are used as signals to begin or change therapeutic strategies and may also be used to predict disease course. However, questions remain regarding the utility of PPFs to predict outcomes, including radiographic progression.
To this end, Tanaka, et al. analysed current understanding of benefits associated with filgotinib on radiographic progression and the relevance of baseline factors.
Keywords:
